Literature DB >> 24975498

T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzee.

Benoit Callendret1, Heather B Eccleston, Shelby Hall, William Satterfield, Stefania Capone, Antonella Folgori, Riccardo Cortese, Alfredo Nicosia, Christopher M Walker.   

Abstract

UNLABELLED: Memory CD8+ T cells generated by spontaneous resolution of hepatitis C virus (HCV) infection rapidly control secondary infections and reduce the risk of virus persistence. Here, CD8+ T-cell immunity and response to reinfection were assessed in a chimpanzee cured of an earlier chronic infection with an interferon (IFN)-free antiviral regimen. CD8+ T cells expanded from liver immediately before and 2 years after cure of chronic infection with two direct-acting antivirals (DAAs) targeted epitopes in the E2, nonstructural (NS)5a, and NS5b proteins. A second infection to assess CD8+ T-cell responsiveness resulted in rapid suppression of HCV replication by week 2, but viremia rebounded 3 weeks later and the infection persisted. The E2, NS5a, and NS5b proteins remained dominant CD8+ T-cell targets after reinfection. Resurgent HCV replication was temporally associated with mutational escape of NS5a and NS5b class I epitopes that had also mutated during the first chronic infection. Two epitopes in E2 remained intact throughout both persistent infections. Intrahepatic CD8+ T cells targeting intact and escape-prone epitopes differed in expression of phenotypic markers of functional exhaustion 2 years after successful DAA therapy and in the capacity to expand in liver upon reinfection.
CONCLUSIONS: The intrahepatic HCV-specific CD8+ T-cell repertoire established during chronic infection was narrowly focused, but very stable, after cure with DAA. Existing intrahepatic CD8+ T cells targeting dominant epitopes of the challenge virus failed to prevent persistence. Vaccination after DAA cure may be necessary to broaden T-cell responses and reduce the risk of a second persistent infection.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24975498      PMCID: PMC4242208          DOI: 10.1002/hep.27278

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  39 in total

1.  Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection.

Authors:  Jason Grebely; Son Truong Pham; Gail V Matthews; Kathy Petoumenos; Rowena A Bull; Barbara Yeung; William Rawlinson; John Kaldor; Andrew Lloyd; Margaret Hellard; Gregory J Dore; Peter A White
Journal:  Hepatology       Date:  2012-02-29       Impact factor: 17.425

2.  Factors that determine the antiviral efficacy of HCV-specific CD8(+) T cells ex vivo.

Authors:  Bianca Seigel; Bertram Bengsch; Volker Lohmann; Ralf Bartenschlager; Hubert E Blum; Robert Thimme
Journal:  Gastroenterology       Date:  2012-11-07       Impact factor: 22.682

3.  Attrition of bystander CD8 T cells during virus-induced T-cell and interferon responses.

Authors:  J M McNally; C C Zarozinski; M Y Lin; M A Brehm; H D Chen; R M Welsh
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

4.  Antigen-independent memory CD8 T cells do not develop during chronic viral infection.

Authors:  E John Wherry; Daniel L Barber; Susan M Kaech; Joseph N Blattman; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-25       Impact factor: 11.205

5.  Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees.

Authors:  Steven S Carroll; Steven Ludmerer; Larry Handt; Kenneth Koeplinger; Nanyan Rena Zhang; Donald Graham; Mary-Ellen Davies; Malcolm MacCoss; Daria Hazuda; David B Olsen
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

6.  Hepatitis C virus (HCV) sequence variation induces an HCV-specific T-cell phenotype analogous to spontaneous resolution.

Authors:  Victoria Kasprowicz; Yu-Hoi Kang; Michaela Lucas; Julian Schulze zur Wiesch; Thomas Kuntzen; Vicki Fleming; Brian E Nolan; Steven Longworth; Andrew Berical; Bertram Bengsch; Robert Thimme; Lia Lewis-Ximenez; Todd M Allen; Arthur Y Kim; Paul Klenerman; Georg M Lauer
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

Review 7.  Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies.

Authors:  Georg M Lauer
Journal:  J Infect Dis       Date:  2013-03       Impact factor: 5.226

Review 8.  Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence.

Authors:  Barbara Rehermann
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

9.  Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.

Authors:  Mark S Sulkowski; David F Gardiner; Maribel Rodriguez-Torres; K Rajender Reddy; Tarek Hassanein; Ira Jacobson; Eric Lawitz; Anna S Lok; Federico Hinestrosa; Paul J Thuluvath; Howard Schwartz; David R Nelson; Gregory T Everson; Timothy Eley; Megan Wind-Rotolo; Shu-Pang Huang; Min Gao; Dennis Hernandez; Fiona McPhee; Diane Sherman; Robert Hindes; William Symonds; Claudio Pasquinelli; Dennis M Grasela
Journal:  N Engl J Med       Date:  2014-01-16       Impact factor: 91.245

10.  Exploratory study of oral combination antiviral therapy for hepatitis C.

Authors:  Fred Poordad; Eric Lawitz; Kris V Kowdley; Daniel E Cohen; Thomas Podsadecki; Sara Siggelkow; Michele Heckaman; Lois Larsen; Rajeev Menon; Gennadiy Koev; Rakesh Tripathi; Tami Pilot-Matias; Barry Bernstein
Journal:  N Engl J Med       Date:  2013-01-03       Impact factor: 91.245

View more
  31 in total

Review 1.  Designing an HCV vaccine: a unique convergence of prevention and therapy?

Authors:  Christopher M Walker
Journal:  Curr Opin Virol       Date:  2017-05-25       Impact factor: 7.090

Review 2.  Progress toward approval of an HCV vaccine.

Authors:  John Lm Law; Mike Logan; Amir Landi; D Lorne Tyrrell; Michael Houghton
Journal:  Can Liver J       Date:  2018-10-03

Review 3.  T cell responses during HBV and HCV infections: similar but not quite the same?

Authors:  Naglaa H Shoukry; Christopher M Walker
Journal:  Curr Opin Virol       Date:  2021-10-04       Impact factor: 7.121

4.  Acetaldehyde accelerates HCV-induced impairment of innate immunity by suppressing methylation reactions in liver cells.

Authors:  Murali Ganesan; Jinjin Zhang; Tatiana Bronich; Larisa I Poluektova; Terrence M Donohue; Dean J Tuma; Kusum K Kharbanda; Natalia A Osna
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-08-06       Impact factor: 4.052

Review 5.  Hepatitis C virus: why do we need a vaccine to prevent a curable persistent infection?

Authors:  Christopher M Walker; Arash Grakoui
Journal:  Curr Opin Immunol       Date:  2015-08-01       Impact factor: 7.486

Review 6.  Immune responses and immunopathology in acute and chronic viral hepatitis.

Authors:  Eui-Cheol Shin; Pil Soo Sung; Su-Hyung Park
Journal:  Nat Rev Immunol       Date:  2016-07-04       Impact factor: 53.106

7.  Persistent hepatitis C viral replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and a direct-acting antiviral.

Authors:  Benoit Callendret; Heather B Eccleston; William Satterfield; Stefania Capone; Antonella Folgori; Riccardo Cortese; Alfredo Nicosia; Christopher M Walker
Journal:  Hepatology       Date:  2015-12-18       Impact factor: 17.425

Review 8.  Mutational escape of CD8+ T cell epitopes: implications for prevention and therapy of persistent hepatitis virus infections.

Authors:  Joerg Timm; Christopher M Walker
Journal:  Med Microbiol Immunol       Date:  2014-12-24       Impact factor: 3.402

9.  Antibodies to an interfering epitope in hepatitis C virus E2 can mask vaccine-induced neutralizing activity.

Authors:  Alla Kachko; Sharon E Frey; Lev Sirota; Ranjit Ray; Frances Wells; Iryna Zubkova; Pei Zhang; Marian E Major
Journal:  Hepatology       Date:  2015-10-16       Impact factor: 17.425

Review 10.  Modeling HCV disease in animals: virology, immunology and pathogenesis of HCV and GBV-B infections.

Authors:  Cordelia Manickam; R Keith Reeves
Journal:  Front Microbiol       Date:  2014-12-08       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.